AbbVie Inc. (ABBV)
| Market Cap | 438.19B +26.4% |
| Revenue (ttm) | 64.39B +10.4% |
| Net Income | 6.27B +67.7% |
| EPS | 3.54 +68.5% |
| Shares Out | 1.77B |
| PE Ratio | 70.05 |
| Forward PE | 16.35 |
| Dividend | $6.92 (2.79%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 4,209,893 |
| Open | 245.65 |
| Previous Close | 246.04 |
| Day's Range | 244.03 - 248.01 |
| 52-Week Range | 190.75 - 267.47 |
| Beta | 0.28 |
| Analysts | Buy |
| Price Target | 274.36 (+10.64%) |
| Earnings Date | Jul 31, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $274.36, which is an increase of 10.64% from the latest price.
News
AbbVie price target raised to $260 from $246 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on AbbVie (ABBV) to $260 from $246 and keeps an Outperform rating on the shares.
AbbVie upgraded to Buy from Hold at Erste Group
Erste Group upgraded AbbVie (ABBV) to Buy from Hold. AbbVie recently raised its 2026 revenue forecast slightly and has made significant progress in its pipeline in the areas of immunology,…
AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA
Allergan Aesthetics, an AbbVie (ABBV) company, announced the FDA has accepted for review its supplemental Biologics License Application for Botox Cosmetic for the temporary improvement in the appearan...
AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic
Allergan Aesthetics, an AbbVie (ABBV) company, announced the U.S. FDA has accepted for review its supplemental Biologics License Application for Botox Cosmetic for the temporary improvement in the app...
Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission i...
AbbVie price target raised to $288 from $261 at Guggenheim
Guggenheim raised the firm’s price target on AbbVie (ABBV) to $288 from $261 and keeps a Buy rating on the shares. The firm updated its model for the “solid” Q2…
AbbVie price target raised to $285 from $265 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $285 from $265 and keeps an Overweight rating on the shares. AbbVie delivered a strong quarter with broad-based beats,…
AbbVie price target raised to $296 from $278 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $296 from $278 and keeps an Overweight rating on the shares following a top-line beat in Q2 and slightly…
AbbVie price target raised to $290 from $282 at Canaccord
Canaccord raised the firm’s price target on AbbVie (ABBV) to $290 from $282 and keeps a Buy rating on the shares. The irm said in yet another nice revenue beat-and-raise…
AbbVie says ‘quite pleased’ with Skyrizi momentum
Says “very excited” about oncology portfolio.
AbbVie raises FY26 revenue view to about $67.6B from about $67.3B
FY26 consensus $67.27B.
AbbVie sees Q3 adjusted EPS $3.84-$3.88, consensus $3.84
Sees Q3 revenue about $17.2B, consensus $17.3B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
Sees FY26 adjusted operating margin approaching 47% of sales. Sees FY26 tax rate 14.5%.
AbbVie says continues to make ‘excellent progress’ advancing pipeline
Says immunology pipeline a “major growth driver” long term. Says long term outlook remains “very strong.” Comments taken from Q2 earnings conference call.
AbbVie Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations with double-digit revenue growth and raised full-year guidance. Immunology and neuroscience segments drove performance, while the Apogee acquisition and new product approvals strengthen the long-term outlook.
AbbVie Earnings release: Q2 2026
AbbVie released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
AbbVie Quarterly report: Q2 2026
AbbVie has published its Q2 2026 quarterly earnings report on July 31, 2026.
AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.
AbbVie cuts its full-year guidance to account for its pending acquisition of Apogee Therapeutics.
AbbVie reports Q2 adjusted EPS $3.65, consensus $3.61
Reports Q2 revenue $16.99, consensus $16.76B. “AbbVie (ABBV) delivered another excellent quarter, marked by outstanding execution and pipeline advancement. We also announced the proposed acquisition o...
AbbVie cuts FY26 adjusted EPS view to $13.87-$14.07 from $13.91-$14.11
FY26 consensus $14.12. “AbbVie (ABBV) is updating its adjusted diluted EPS guidance to include the impact of the proposed Apogee Therapeutics acquisition, which is expected to be $0.14 dilutive in…
AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
AbbVie trimmed its 2026 profit forecast on Friday to account for its planned Apogee Therapeutics acquisition, while topping second-quarter estimates on strong immunology drug sales.
AbbVie Reports Second-Quarter 2026 Financial Results
Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Percent; These Results Include an Unfavorable Impact of $0...
JUVÉDERM® Day Returns to U.S. on August 19
Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. F...
AbbVie announces Elahere availability in Singapore
AbbVie (ABBV) announced availability of Elahere in Singapore for the treatment of Platinum-Resistant Ovarian Cancer. Elahere is the first and only antibody-drug conjugate therapy approved specifically...